Literature DB >> 16168789

Management of depression in primary care: a survey of general practitioners in Spain.

Belén Martín-Agueda1, Francisco López-Muñoz, Gabriel Rubio, José A Guerra, Agustín Silva, Cecilio Alamo.   

Abstract

OBJECTIVE: The objective of this study was to analyze the current situation of health care for depression in Spain according to general practitioners' (GPs') opinion and how it has evolved over the last 20 years on the basis of comparisons with the results of two previous social-health studies (published in 1997 and 1982).
METHOD: Throughout 2002, we recorded the opinions of 238 GPs after asking them to fill up structured questionnaires in which they rated care, clinical, therapeutic and care quality aspects.
RESULTS: Only 40% of patients with depression visit a doctor, implying a very high level of "concealed epidemiology." The diagnostic instruments most commonly used are assessment of symptoms and patient interview. Pharmacological treatment is the option GPs most commonly choose once a depression diagnosis is established (80% vs. 50% in 1997; P<.001). Selective serotonin reuptake inhibitors (SSRIs), together with anxiolytics, are the drugs most commonly used in the treatment of depression. SSRIs are the first choice drugs, being preferred to tricyclic antidepressants and anxiolytics, which were the most popular options for GPs in the 1997 survey. Areas where there is a need for improvement are time devoted to consultation, coordination between GPs and psychiatrists and waiting lists.
CONCLUSIONS: The quality of health care for depression has improved in recent years, thanks to changes in the attitudes of GPs and the evolution of pharmacological treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16168789     DOI: 10.1016/j.genhosppsych.2005.05.002

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  7 in total

1.  Treatment and follow-up of anxiety and depression in clinical-scenario patients: survey of Saskatchewan family physicians.

Authors:  Julie Kosteniuk; Debra Morgan; Carl D'Arcy
Journal:  Can Fam Physician       Date:  2012-03       Impact factor: 3.275

2.  [Attitudes and opinions of family doctors on depression: application of the Depression Attitudes Questionnaire (DAQ)].

Authors:  Enric Aragonès; Josep Lluís Piñol; Germán López-Cortacans; Josep Maria Hernández; Antonia Caballero
Journal:  Aten Primaria       Date:  2011-01-12       Impact factor: 1.137

3.  General practitioners and patients with psychological stress at work.

Authors:  M Souville; S Cabut; A Viau; G Iarmarcovai; S Arnaud; P Verger
Journal:  J Occup Rehabil       Date:  2009-05-22

4.  General practitioners' choices and their determinants when starting treatment for major depression: a cross sectional, randomized case-vignette survey.

Authors:  Hélène Dumesnil; Sébastien Cortaredona; Hélène Verdoux; Rémy Sebbah; Alain Paraponaris; Pierre Verger
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

5.  Depression in primary care: interpersonal counseling vs selective serotonin reuptake inhibitors. The DEPICS Study. A multicenter randomized controlled trial. Rationale and design.

Authors:  Marco Menchetti; Biancamaria Bortolotti; Paola Rucci; Paolo Scocco; Annarosa Bombi; Domenico Berardi
Journal:  BMC Psychiatry       Date:  2010-11-25       Impact factor: 3.630

6.  Pattern of Antidepressant Utilization and Cost in Iran from 2006 to 2013 in Comparison with Other Countries.

Authors:  Fatemeh Soleymani; Forouzan Taheri; Elizabeth Roughead; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  J Epidemiol Glob Health       Date:  2018-12

7.  Primary care physicians' perspective on the management of anxiety and depressive disorders: a cross-sectional survey in Emilia Romagna Region.

Authors:  Federica Casini; Cecilia Sighinolfi; Paola Tedesco; Pier Venanzio Bandieri; Maria Bologna; Niccolò Colombini; Clara Curcetti; Michele Magnani; Mara Morini; Alberto Serio; Ilaria Tarricone; Domenico Berardi; Marco Menchetti
Journal:  BMC Fam Pract       Date:  2013-06-07       Impact factor: 2.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.